Merck (MRK +2.1%) net profit $781M vs $908M a year earlier,
Earnings were hurt by patent expirations and currency fluctuations.
Sales breakdown: Pharmaceuticals flat at $9.76B, with Januvia +4%, Zetia +9%, Remicade +9%, Janumet +11%, Gardasil -9%; Animal Health -1%, consumer care +1%.
Guidance: 2014 adjusted EPS of $3.35-3.53 vs consensus of $3.48; revenues $42.4-43.2B vs $43.35B. (PR)